KISSIMMEE, Fla., July 30, 2026 — Research on Taphalgin® (lumekefamide), PVP Labs’ lead investigational candidate, was selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a scientific forum focused on the medical needs of deployed service members.
Selection for presentation at MHSRS does not imply endorsement by MHSRS, the Military Health System, the Defense Health Agency or the U.S. Government.
Chief Medical Officer Joe Stauffer, D.O., MBA, FAPCR, a former U.S. Navy physician and former FDA Medical Review Officer, will present the company’s research on Wednesday, August 5, 2026, at 4:00 PM in Kissimmee, Florida.
Research Presented at MHSRS 2026
Analgesia in combat and prolonged field care is a distinct scientific and operational problem. MHSRS is one of the forums where this problem is discussed with the military clinicians and researchers who work on it.
The presentation will cover the candidate’s pharmacology and the development program to date. The company describes lumekefamide, an investigational candidate, as acting through selective μ1-opioid receptor agonism combined with calcium-channel modulation.
Source: PVP Labs press release, July 30, 2026 (Business Wire).
Important information
Taphalgin® (lumekefamide) is an investigational product. It has not been approved by the U.S. Food and Drug Administration or the European Medicines Agency, and its safety and efficacy have not been established for any use in these jurisdictions. This content is provided for scientific and informational purposes only. It is not medical advice, not an offer to sell, and not a solicitation of any product.
Any references to human exposure, clinical experience, or regulatory interactions relate only to non-U.S. markets or to preliminary development activities and do not imply U.S. FDA approval, U.S. safety, or U.S. efficacy.
About PVP Labs
PVP Labs is a Singapore-based peptide biotechnology company developing peptide therapeutics across analgesia, antiviral and tissue-repair indications.
